Video directly observed therapy intervention using a mobile health application among opioid use disorder patients receiving office-based buprenorphine treatment: protocol for a pilot randomized controlled trial

Schramm, Zachery A.; Radick, Andrea C.; Ventura, Alicia S.; Klein, Jared W.; Samet, Jeffrey H.; Saxon, Andrew J.; Kim, Theresa; Tsui, Judith I.

doi:10.1186/s13722-020-00203-9

Cited by 13 publications

(11 citation statements)

References 61 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The flexibility of telehealth to support opioid agonist therapy adherence offers an effective alternative to in-person care with people 50% more likely to be retained in therapy for 1 year compared to 39% for those treated in person ( 18 ). These results support findings from other studies, demonstrating that telemedicine-delivered OAT is a comparable treatment modality with the potential to expand access to treatment for those with opioid use disorder and may be an effective and appropriate alternative to traditional face-to-face treatment modalities ( 18 , 20 , 42 ).…”

Section: Discussionsupporting

confidence: 88%

Digital Interventions to Save Lives From the Opioid Crisis Prior and During the SARS COVID-19 Pandemic: A Scoping Review of Australian and Canadian Experiences

Donnell

Unnithan

Tyndall

et al. 2022

Front. Public Health

View full text Add to dashboard Cite

BackgroundThe potential for digital initiatives for opioid harm reduction is boundless. Synthesized evidence on current interventions and their efficacy are emerging. This scoping review is an effort to aggregate Canadian and Australian digital health initiatives used to prevent opioid-related deaths and minimize harm, prior to and particularly during the pandemic of SARs-COVID-19, when the crisis escalated.MethodsThe Joanna Briggs Institute's methodological framework for conducting scoping reviews was used. Peer reviewed and gray literature published between January 2016 to October 2021 were included. Search translation was performed across CINAHL, Cochrane, SCOPUS, MEDLINE Complete, and ProQuest Public Health with consistent use of key search terms. Citation checks were also conducted. Studies included were written in English and reported on digital technologies to prevent opioid-related harm and/or mortality in participants aged 18 years or older in Australia and Canada.ResultsA total of 16 publications were included in the final analysis (Australia = 5; Canada = 11). The most frequently reported digital technologies were telehealth to support access to treatment (n = 3) and mobile applications for overdose monitoring and prevention (n = 3). Telehealth-delivered opioid replacement therapy demonstrated equal outcomes and treatment retention rates compared to in-person and mobile applications for overdose monitoring demonstrated lifesaving capability through direct linkages with emergency response services.ConclusionsDigital interventions to minimize opioid crisis related harm and overdose prevention are fast emerging in Australia and Canada. During the pandemic, the crisis escalated in both countries as a public health emergency, and different initiatives were trialed. Digital harm reduction solutions via mobile apps (or SaaS solutions) were found to have the potential to prevent accidental overdose deaths and save lives, if rendered through privacy preserved, secure and trust enabled methods that empower users. Knowledge sharing between the two countries, relating to suitable interventions, may add significant value in combatting the escalating opioid crisis in the post pandemic era.

show abstract

Section: Discussionsupporting

confidence: 88%

Digital Interventions to Save Lives From the Opioid Crisis Prior and During the SARS COVID-19 Pandemic: A Scoping Review of Australian and Canadian Experiences

Donnell

Unnithan

Tyndall

et al. 2022

Front. Public Health

View full text Add to dashboard Cite

show abstract

“…It is particularly important for vulnerable populations, like people who inject drugs (PWID), who may have low study retention rates due to participant-related barriers like unstable housing 3 . Indeed, some researchers are developing mHealth protocols to support substance use disorder treatment efforts, 4 – 6 and mHealth has proven successful, at least in the short-term, in several U.S.-based studies using text-message or web-based interventions. For example, mHealth has been used to support smoking cessation 7 , 8 increase HIV anti-retroviral therapy adherence among patients with comorbid substance use disorders 9 , 10 , and improve Hepatitis C testing and health outcomes among patients with an opioid use disorder 11 .…”

Section: Introductionmentioning

confidence: 99%

Mobile Phone and Internet use among People who Inject Drugs: Implications for Mobile Health Interventions

et al. 2022

View full text Add to dashboard Cite

Background: Mobile health (mHealth) interventions have the potential to improve substance use treatment engagement and outcomes, and to reduce risk behaviors among people who inject drugs (PWID). However, there are few studies assessing mobile technology use among PWID and none have investigated continuity of mobile phone use. Methods: We surveyed 494 PWID. We used bivariate (independent-sample t- and chi-square tests) and multivariate (logistic regression) analyses to determine whether mobile phone and/or internet use differed as a function of participant- and/or injection-related characteristics. Results: Most participants (77%) had a mobile phone, with 67% having a phone that was free of charge. Participants with a phone were significantly less likely to be homeless (AOR = 0.28), to have shared syringes (AOR = 0.53), and to have reused syringes (AOR = 0.26) in the past 3 months. We observed high rates of phone and number turnover, with more than half reporting that they got a new phone (57%) and/or number (56%) at least once within the past 3 months. Most participants were familiar with using the internet (80% ever use), though participants who had ever used the internet were younger (AOR = 0.89), were less likely to be homeless (AOR = 0.38), were less likely to have shared syringes (AOR = 0.49), and were more likely to have injected methamphetamine by itself (AOR = 2.49) in the past 3 months. Conclusions: Overall, mobile technology and internet use was high among our sample of PWID. Several factors should be considered in recruiting diverse samples of PWID to minimize bias in mHealth study outcomes, including mobile phone access and protocol type (text- vs internet-based).

show abstract

“…Most participants had a baseline dosing frequency of 2 or more times daily (77%). Participants had a median and interquartile range of 14 (7)(8)(9)(10)(11)(12)(13)(14)(15)(16)(17)(18)(19)(20)(21) days in treatment at baseline.…”

Section: Resultsmentioning

confidence: 99%

“…Patients were excluded from the TAAB study if they were unable or unwilling to use the mobile application, unable to provide informed consent, or unavailable because of imminent relocation or incarceration. Further details of the TAAB study design, protocol, and underlying theoretical framework have been published previously 7,9 …”

Section: Methodsmentioning

confidence: 99%

Use of Video Directly Observed Therapy and Characteristics Associated With Use Among Patients Treated With Buprenorphine in an Office-based Setting

et al. 2022

Self Cite

View full text Add to dashboard Cite

ObjectivesVideo directly observed therapy (video DOT) is a tool for confirming buprenorphine adherence that could complement the use of urine toxicology; research is needed to characterize the patients who are receptive and able to use this technology. We aimed to describe video DOT utilization and assess participant characteristics associated with use.MethodsWe performed a secondary analysis of data from a pilot randomized controlled trial of adults who recently initiated sublingual buprenorphine in office-based programs, restricting to intervention arm participants, which consisted of 12 weeks of video DOT via a mobile health technology platform. Participants were instructed to record at least 1 daily video of buprenorphine self-administration. Poisson regression models with robust standard errors were used to measure associations between participant characteristics and frequency of submitted videos.ResultsThe sample included 39 participants. Of 3276 possible videos, 1002 (31%) were submitted. Age ≥40 years (relative risk [RR], 2.54 [95% confidence interval {CI}, 1.31–4.91]) and once-daily buprenorphine dosing (RR, 3.10 [95% CI, 1.76–5.48]) were positively associated with video submissions. Non-White race (RR, 0.43 [95% CI, 0.19–0.97]), less than high school education (RR, 0.27 [95% CI, 0.10–0.74]), history of previous buprenorphine treatment (RR, 0.50 [95% CI, 0.25–0.97]), and ≥3 previous treatment attempts (RR, 0.16 [95% CI, 0.07–0.37]) were negatively associated.ConclusionsVideo DOT utilization resulted in about a third of expected videos, although there were differences in use according to age, race, buprenorphine treatment factors, and educational status. Such differences underscore that mobile-health interventions such as video DOT may not be equally used by all patients.Trial Registration: ClinicalTrails.gov, NCT03779997, registered on December 19, 2018.

show abstract

Video directly observed therapy intervention using a mobile health application among opioid use disorder patients receiving office-based buprenorphine treatment: protocol for a pilot randomized controlled trial

Cited by 13 publications

References 61 publications

Digital Interventions to Save Lives From the Opioid Crisis Prior and During the SARS COVID-19 Pandemic: A Scoping Review of Australian and Canadian Experiences

Digital Interventions to Save Lives From the Opioid Crisis Prior and During the SARS COVID-19 Pandemic: A Scoping Review of Australian and Canadian Experiences

Mobile Phone and Internet use among People who Inject Drugs: Implications for Mobile Health Interventions

Use of Video Directly Observed Therapy and Characteristics Associated With Use Among Patients Treated With Buprenorphine in an Office-based Setting

Contact Info

Product

Resources

About